These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 12072777)
1. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma. Rabinowitz I; Telepak R; Lee FC Clin Nucl Med; 2002 Jul; 27(7):499-502. PubMed ID: 12072777 [TBL] [Abstract][Full Text] [Related]
2. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. Takayasu K; Furukawa H; Wakao F; Muramatsu Y; Abe H; Terauchi T; Winter TC; Sakamoto M; Hirohashi S AJR Am J Roentgenol; 1995 Apr; 164(4):885-90. PubMed ID: 7726041 [TBL] [Abstract][Full Text] [Related]
4. Imaging of somatostatin receptor subtype 2 in advanced hepatocellular carcinoma by 68Ga-DOTATOC PET. Freesmeyer M; Schulz S; Knösel T; Settmacher U Nuklearmedizin; 2009; 48(3):N17-8. PubMed ID: 19588574 [No Abstract] [Full Text] [Related]
5. Positive octreotide scan in a case of hepatocellular carcinoma. Schommartz B; Brill N; Larisch R; Wettstein M; Häussinger D; Müller-Gärtner HW J Hepatol; 2002 Oct; 37(4):539. PubMed ID: 12217610 [No Abstract] [Full Text] [Related]
6. 111In-octreotide scintigraphy in small cell lung cancer. Semprebene A; Ferraironi A; Franciotti G; Venturo I; Giunta S; Lopez M; Maini CL Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):108-10. PubMed ID: 9002764 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of early-phase-enhanced computed tomography for the differentiation of pulmonary metastases from hepatocellular carcinoma and primary lung cancer. Choi JI; Choi HJ; Jung DC; Kim MJ; Hong EK; Park JW; Jang YJ; Kim CM Acta Radiol; 2009 Nov; 50(9):1005-10. PubMed ID: 19863410 [TBL] [Abstract][Full Text] [Related]
8. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Markidou S; Panagiotakos D; Chrysohoou C; Bazinis A; Paraskevas E Hepatogastroenterology; 2002; 49(47):1245-50. PubMed ID: 12239914 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356 [TBL] [Abstract][Full Text] [Related]
10. Solitary splenic metastasis from hepatocellular carcinoma detected on (18)F-FDG PET/CT. Kim DH; Jeong SY; Lee SW; Lee J; Ahn BC Clin Nucl Med; 2015 Jun; 40(6):e325-7. PubMed ID: 25546205 [TBL] [Abstract][Full Text] [Related]
11. Iso-intense gallium uptake in hepatocellular carcinoma: potential pitfalls in diagnosis. Lee VW; Staffa M Nucl Med Commun; 1988 Apr; 9(4):309-15. PubMed ID: 2840616 [TBL] [Abstract][Full Text] [Related]
14. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma. Deming DA; Stella AL; Holen KD; Ku G; O'Reilly EM Clin Adv Hematol Oncol; 2005 Jun; 3(6):468-72; discussion 472-4. PubMed ID: 16167024 [No Abstract] [Full Text] [Related]
15. Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1. Huang CZ; Huang AM; Liu JF; Wang B; Lin KC; Ye YB Cell Physiol Biochem; 2018; 47(6):2340-2349. PubMed ID: 29990987 [TBL] [Abstract][Full Text] [Related]
16. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Liu HL; Huo L; Wang L Acta Pharmacol Sin; 2004 Oct; 25(10):1380-6. PubMed ID: 15456543 [TBL] [Abstract][Full Text] [Related]
17. [The lung and mediastinal metastases of a hepatocellular carcinoma. Enhancement in the liver function scintigram with 99mTc-IODIDA]. Link TM; Anger K; Hebestreit HP; Bade J Rofo; 1992 Jul; 157(1):101-2. PubMed ID: 1322200 [No Abstract] [Full Text] [Related]
18. Tc-99m HIDA hepatobiliary agent in the diagnosis of pulmonary metastasis from hepatocellular carcinoma. Wang PW; Tai DI; Chen HY Clin Nucl Med; 1991 Feb; 16(2):120-3. PubMed ID: 1848494 [TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Jois B; Asopa R; Basu S Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668 [TBL] [Abstract][Full Text] [Related]
20. 11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma. Delbeke D; Pinson CW J Nucl Med; 2003 Feb; 44(2):222-3. PubMed ID: 12571213 [No Abstract] [Full Text] [Related] [Next] [New Search]